

Ronald Simon

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7256537/ronald-simon-publications-by-year.pdf>

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

401
papers

17,421
citations

65
h-index

120
g-index

422
ext. papers

19,942
ext. citations

6.3
avg, IF

5.8
L-index

#	Paper	IF	Citations
401	Carboxypeptidase A1 (CPA1) Immunohistochemistry Is Highly Sensitive and Specific for Acinar Cell Carcinoma (ACC) of the Pancreas. <i>American Journal of Surgical Pathology</i> , 2022 , 46, 97-104	6.7	2
400	Cytokeratin 7 and cytokeratin 20 expression in cancer: A tissue microarray study on 15,424 cancers.. <i>Experimental and Molecular Pathology</i> , 2022 , 104762	4.4	0
399	Trophoblast Cell Surface Antigen 2 Expression in Human Tumors: A Tissue Microarray Study on 18,563 Tumors.. <i>Pathobiology</i> , 2022 , 1-14	3.6	1
398	Large-Scale Tissue Microarray Evaluation Corroborates High Specificity of High-Level Arginase-1 Immunostaining for Hepatocellular Carcinoma.. <i>Diagnostics</i> , 2021 , 11,	3.8	1
397	P02.06 Semi-automated validation and quantification of CTLA-4 in 90 different Tumor entities using multiple antibodies and artificial intelligence 2021 , 9, A9.3-A10		
396	P02.03 Automated cell type specific PD-L1 quantification by artificial intelligence using high throughput bleach & stain 15-marker multiplex fluorescence immunohistochemistry in human cancers 2021 , 9, A8.2-A9		
395	DOG1 expression is common in human tumors: A tissue microarray study on more than 15,000 tissue samples. <i>Pathology Research and Practice</i> , 2021 , 228, 153663	3.4	2
394	6q deletion is frequent but unrelated to patient prognosis in breast cancer. <i>Breast Cancer</i> , 2021 , 1	3.4	
393	Semi-automated validation and quantification of CTLA-4 in 90 different Tumor entities using multiple antibodies and artificial intelligence. <i>American Journal of Clinical Pathology</i> , 2021 , 156, S137-S138	1.9	
392	Elevated MUC5AC expression is associated with mismatch repair deficiency and proximal tumor location but not with cancer progression in colon cancer. <i>Medical Molecular Morphology</i> , 2021 , 54, 156-165	2.3	5
391	Mismatch repair deficiency occurs very rarely in seminomas. <i>Translational Andrology and Urology</i> , 2021 , 10, 1048-1055	2.3	1
390	Napsin A Expression in Human Tumors and Normal Tissues. <i>Pathology and Oncology Research</i> , 2021 , 27, 613099	2.6	2
389	Prognostic role of proliferating CD8 cytotoxic Tcells in human cancers. <i>Cellular Oncology (Dordrecht)</i> , 2021 , 44, 793-803	7.2	4
388	Tumor cell PD-L1 expression is a strong predictor of unfavorable prognosis in immune checkpoint therapy-naive clear cell renal cell cancer. <i>International Urology and Nephrology</i> , 2021 , 53, 2493-2503	2.3	2
387	Mesothelin Expression in Human Tumors: A Tissue Microarray Study on 12,679 Tumors. <i>Biomedicines</i> , 2021 , 9,	4.8	9
386	Prevalence of proliferating CD8 cells in normal lymphatic tissues, inflammation and cancer. <i>Aging</i> , 2021 , 13, 14590-14603	5.6	3
385	E-Cadherin expression in human tumors: a tissue microarray study on 10,851 tumors. <i>Biomarker Research</i> , 2021 , 9, 44	8	3

384	Increased lysophosphatidylcholine acyltransferase 1 expression is unrelated to prognosis of esophageal cancer patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021 , 147, 2879-2884	4.9	0
383	High density of cytotoxic T-lymphocytes is linked to tumoral PD-L1 expression regardless of the mismatch repair status in colorectal cancer. <i>Acta Oncologica</i> , 2021 , 60, 1210-1217	3.2	1
382	High level of EZH2 expression is linked to high density of CD8-positive T-lymphocytes and an aggressive phenotype in renal cell carcinoma. <i>World Journal of Urology</i> , 2021 , 39, 481-490	4	4
381	A non-diploid DNA status is linked to poor prognosis in renal cell cancer. <i>World Journal of Urology</i> , 2021 , 39, 829-837	4	3
380	Chromosome 5 harbors two independent deletion hotspots at 5q13 and 5q21 that characterize biologically different subsets of aggressive prostate cancer. <i>International Journal of Cancer</i> , 2021 , 148, 748-758	7.5	2
379	MUC5AC Expression in Various Tumor Types and Nonneoplastic Tissue: A Tissue Microarray Study on 10 399 Tissue Samples. <i>Technology in Cancer Research and Treatment</i> , 2021 , 20, 15330338211043328	2.7	2
378	Reduced anoctamin 7 (ANO7) expression is a strong and independent predictor of poor prognosis in prostate cancer. <i>Cancer Biology and Medicine</i> , 2021 , 18, 245-255	5.2	1
377	Overexpression of the TRIM24 E3 Ubiquitin Ligase is Linked to Genetic Instability and Predicts Unfavorable Prognosis in Prostate Cancer. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2021 , 29, e29-e38	1.9	0
376	p63 expression in human tumors and normal tissues: a tissue microarray study on 10,200 tumors. <i>Biomarker Research</i> , 2021 , 9, 7	8	4
375	Opposing prognostic relevance of junction plakoglobin in distinct prostate cancer patient subsets. <i>Molecular Oncology</i> , 2021 , 15, 1956-1969	7.9	0
374	Diagnostic and prognostic impact of cytokeratin 18 expression in human tumors: a tissue microarray study on 11,952 tumors. <i>Molecular Medicine</i> , 2021 , 27, 16	6.2	5
373	Y-chromosome loss is frequent in male renal tumors. <i>Annals of Translational Medicine</i> , 2021 , 9, 209	3.2	2
372	MUC5AC expression is linked to mucinous/endometrioid subtype, absence of nodal metastasis and mismatch repair deficiency in ovarian cancer. <i>Pathology Research and Practice</i> , 2021 , 224, 153533	3.4	1
371	Mesothelin is Commonly Expressed in Pancreatic Adenocarcinoma but Unrelated to Cancer Aggressiveness. <i>Cancer Investigation</i> , 2021 , 39, 711-720	2.1	1
370	High mitochondrial content is associated with breast cancer aggressiveness. <i>Molecular and Clinical Oncology</i> , 2021 , 15, 203	1.6	1
369	DOG1 is commonly expressed in pancreatic adenocarcinoma but unrelated to cancer aggressiveness. <i>PeerJ</i> , 2021 , 9, e11905	3.1	1
368	Pattern of placental alkaline phosphatase (PLAP) expression in human tumors: a tissue microarray study on 12,381 tumors. <i>Journal of Pathology: Clinical Research</i> , 2021 , 7, 577-589	5.3	1
367	Diagnostic and prognostic impact of cytokeratin 19 expression analysis in human tumors: a tissue microarray study of 13,172 tumors. <i>Human Pathology</i> , 2021 , 115, 19-36	3.7	4

366	Cytokeratin 5 and cytokeratin 6 expressions are unconnected in normal and cancerous tissues and have separate diagnostic implications. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021 , 1	5.1	0
365	Immunohistochemically detectable thyroglobulin expression in extrathyroidal cancer is 100% specific for thyroidal tumor origin. <i>Annals of Diagnostic Pathology</i> , 2021 , 54, 151793	2.2	3
364	CHD1 loss negatively influences metastasis-free survival in R0-resected prostate cancer patients and promotes spontaneous metastasis in vivo. <i>Cancer Gene Therapy</i> , 2021 ,	5.4	2
363	Lorlatinib Induces Durable Disease Stabilization in a Pancreatic Cancer Patient with a ROS1 p.L1950F Mutation: Case Report. <i>Oncology Research and Treatment</i> , 2021 , 44, 495-502	2.8	1
362	Angiotensin-Converting Enzyme 2 Protein Is Overexpressed in a Wide Range of Human Tumour Types: A Systematic Tissue Microarray Study on >15,000 Tumours.. <i>Biomedicines</i> , 2021 , 9,	4.8	3
361	Upregulation of Phosphatase 1 Nuclear-Targeting Subunit (PNUTS) Is an Independent Predictor of Poor Prognosis in Prostate Cancer. <i>Disease Markers</i> , 2020 , 2020, 7050146	3.2	2
360	Upregulation of the heterogeneous nuclear ribonucleoprotein hnRNPA1 is an independent predictor of early biochemical recurrence in TMPRSS2:ERG fusion-negative prostate cancers. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020 , 477, 625-636	5.1	1
359	Chromosome 17p13 deletion is associated with an aggressive tumor phenotype in clear cell renal cell carcinoma. <i>World Journal of Surgical Oncology</i> , 2020 , 18, 128	3.4	2
358	Up regulation of the Hippo signalling effector YAP1 is linked to early biochemical recurrence in prostate cancers. <i>Scientific Reports</i> , 2020 , 10, 8916	4.9	5
357	Upregulation of the transcription factor TFAP2D is associated with aggressive tumor phenotype in prostate cancer lacking the TMPRSS2:ERG fusion. <i>Molecular Medicine</i> , 2020 , 26, 24	6.2	2
356	Loss of the adhesion molecule CEACAM1 is associated with early biochemical recurrence in TMPRSS2:ERG fusion-positive prostate cancers. <i>International Journal of Cancer</i> , 2020 , 147, 575-583	7.5	2
355	Prevalence of CD8 cytotoxic lymphocytes in human neoplasms. <i>Cellular Oncology (Dordrecht)</i> , 2020 , 43, 421-430	7.2	15
354	Homogeneous MMR Deficiency Throughout the Entire Tumor Mass Occurs in a Subset of Colorectal Neuroendocrine Carcinomas. <i>Endocrine Pathology</i> , 2020 , 31, 182-189	4.2	7
353	MMR Deficiency is Homogeneous in Pancreatic Carcinoma and Associated with High Density of Cd8-Positive Lymphocytes. <i>Annals of Surgical Oncology</i> , 2020 , 27, 3997-4006	3.1	13
352	IL22BP Mediates the Antitumor Effects of Lymphotoxin Against Colorectal Tumors in Mice and Humans. <i>Gastroenterology</i> , 2020 , 159, 1417-1430.e3	13.3	11
351	Reduced KLK2 expression is a strong and independent predictor of poor prognosis in ERG-negative prostate cancer. <i>Prostate</i> , 2020 , 80, 1097-1107	4.2	5
350	MMR deficiency in urothelial carcinoma of the bladder presents with temporal and spatial homogeneity throughout the tumor mass. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020 , 38, 488-495	2.8	8
349	Extreme intratumour heterogeneity and driver evolution in mismatch repair deficient gastro-oesophageal cancer. <i>Nature Communications</i> , 2020 , 11, 139	17.4	22

348	High homogeneity of MMR deficiency in ovarian cancer. <i>Gynecologic Oncology</i> , 2020 , 156, 669-675	4.9	13
347	High CHK2 protein expression is a strong and independent prognostic feature in ERG negative prostate cancer. <i>Pathology</i> , 2020 , 52, 421-430	1.6	2
346	Chromosomal deletion of 9p21 is linked to poor patient prognosis in papillary and clear cell kidney cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020 , 38, 605.e1-605.e8	2.8	2
345	Prevalence and clinical significance of VHL mutations and 3p25 deletions in renal tumor subtypes. <i>Oncotarget</i> , 2020 , 11, 237-249	3.3	11
344	Loss of p16 and high Ki67 labeling index is associated with poor outcome in esophageal carcinoma. <i>Oncotarget</i> , 2020 , 11, 1007-1016	3.3	11
343	Loss of cytoplasmic survivin expression is an independent predictor of poor prognosis in radically operated prostate cancer patients. <i>Cancer Medicine</i> , 2020 , 9, 1409-1418	4.8	4
342	High RSF1 protein expression is an independent prognostic feature in prostate cancer. <i>Acta Oncologica</i> , 2020 , 59, 268-273	3.2	4
341	Expression of CCCTC-binding factor (CTCF) is linked to poor prognosis in prostate cancer. <i>Molecular Oncology</i> , 2020 , 14, 129-138	7.9	8
340	High homogeneity of mismatch repair deficiency in advanced prostate cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020 , 476, 745-752	5.1	9
339	High-grade intratumoral tumor budding is a predictor for lymphovascular invasion and adverse outcome in stage II colorectal cancer. <i>International Journal of Colorectal Disease</i> , 2020 , 35, 259-268	3	11
338	8p deletions in renal cell carcinoma are associated with unfavorable tumor features and poor overall survival. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020 , 38, 43.e13-43.e20	2.8	5
337	Claudin-1 upregulation is associated with favorable tumor features and a reduced risk for biochemical recurrence in ERG-positive prostate cancer. <i>World Journal of Urology</i> , 2020 , 38, 2185-2196	4	6
336	TIP5 primes prostate luminal cells for the oncogenic transformation mediated by -loss. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020 , 117, 3637-3647	11.5	11
335	Secreted Frizzled-Related Protein 4 (SFRP4) Is an Independent Prognostic Marker in Prostate Cancers Lacking TMPRSS2: ERG Fusions. <i>Pathology and Oncology Research</i> , 2020 , 26, 2709-2722	2.6	4
334	Ectopic Expression of Hematopoietic SHIP1 in Human Colorectal Cancer. <i>Biomedicines</i> , 2020 , 8,	4.8	1
333	Increased Cytoplasmic CD138 Expression Is Associated with Aggressive Characteristics in Prostate Cancer and Is an Independent Predictor for Biochemical Recurrence. <i>BioMed Research International</i> , 2020 , 2020, 5845374	3	3
332	High B7-H3 expression is linked to increased risk of prostate cancer progression. <i>Pathology International</i> , 2020 , 70, 733-742	1.8	8
331	Xenograft-derived mRNA/miR and protein interaction networks of systemic dissemination in human prostate cancer. <i>European Journal of Cancer</i> , 2020 , 137, 93-107	7.5	4

330	Differential regulation of extracellular matrix proteins in three recurrent liver metastases of a single patient with colorectal cancer. <i>Clinical and Experimental Metastasis</i> , 2020 , 37, 649-656	4.7	3
329	P03.01 Prevalence of CD112R+immune cells in normal lymphatic tissues, inflammation and the cancer microenvironment 2020 , 8, A22.1-A22		
328	P03.10 Prevalence and prognostic role of FoxP3+regulatory T lymphocytes in cancer. A tissue microarray study on >20000 cancers 2020 , 8, A26.1-A26		
327	Discovery of Targetable Genetic Alterations in NSCLC Patients with Different Metastatic Patterns Using a MassARRAY-Based Circulating Tumor DNA Assay. <i>Cells</i> , 2020 , 9,	7.9	7
326	P03.06 Pattern of Ki67+expanding CD8+cytotoxic T cells in healthy tissues, inflammation and the cancer microenvironment 2020 , 8, A24.2-A25		
325	Epithelial splicing regulatory protein 1 and 2 (ESRP1 and ESRP2) upregulation predicts poor prognosis in prostate cancer. <i>BMC Cancer</i> , 2020 , 20, 1220	4.8	3
324	Upregulation of PTTG1 is associated with poor prognosis in prostate cancer. <i>Pathology International</i> , 2020 , 70, 441-451	1.8	4
323	Random forest-based modelling to detect biomarkers for prostate cancer progression. <i>Clinical Epigenetics</i> , 2019 , 11, 148	7.7	32
322	Patterns of TIGIT Expression in Lymphatic Tissue, Inflammation, and Cancer. <i>Disease Markers</i> , 2019 , 2019, 5160565	3.2	31
321	Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors. <i>Cancers</i> , 2019 , 11,	6.6	65
320	Loss of PSP94 expression is associated with early PSA recurrence and deteriorates outcome of deleted prostate cancers. <i>Cancer Biology and Medicine</i> , 2019 , 16, 319-330	5.2	1
319	Hyperparameter optimization for image analysis: application to prostate tissue images and live cell data of virus-infected cells. <i>International Journal of Computer Assisted Radiology and Surgery</i> , 2019 , 14, 1847-1857	3.9	3
318	Immune Exclusion Is Frequent in Small-Cell Carcinoma of the Bladder. <i>Disease Markers</i> , 2019 , 2019, 2532518	5.18	7
317	SNW1 is a prognostic biomarker in prostate cancer. <i>Diagnostic Pathology</i> , 2019 , 14, 33	3	2
316	16p13.11 microdeletion uncovers loss-of-function of a MYH11 missense variant in a patient with megacystis-microcolon-intestinal-hypoperistalsis syndrome. <i>Clinical Genetics</i> , 2019 , 96, 85-90	4	11
315	p53 overexpression is a prognosticator of poor outcome in esophageal cancer. <i>Oncology Letters</i> , 2019 , 17, 3826-3834	2.6	14
314	Aberrant expression of the microtubule-associated protein tau is an independent prognostic feature in prostate cancer. <i>BMC Cancer</i> , 2019 , 19, 193	4.8	13
313	Down-Regulation of S100A8 is an Independent Predictor of PSA Recurrence in Prostate Cancer Treated by Radical Prostatectomy. <i>Neoplasia</i> , 2019 , 21, 872-881	6.4	2

312	Expression of the immune checkpoint receptor TIGIT in seminoma. <i>Oncology Letters</i> , 2019 , 18, 1497-1502.	6
311	The independent prognostic impact of the GATA2 pioneering factor is restricted to ERG-negative prostate cancer. <i>Tumor Biology</i> , 2019 , 41, 1010428318824815	2.9 4
310	High-level expression of protein tyrosine phosphatase non-receptor 12 is a strong and independent predictor of poor prognosis in prostate cancer. <i>BMC Cancer</i> , 2019 , 19, 944	4.8 0
309	A shift from membranous and stromal syndecan-1 (CD138) expression to cytoplasmic CD138 expression is associated with poor prognosis in breast cancer. <i>Molecular Carcinogenesis</i> , 2019 , 58, 2306-2315	5.15 8
308	Up-regulation of lysophosphatidylcholine acyltransferase 1 (LPCAT1) is linked to poor prognosis in breast cancer. <i>Aging</i> , 2019 , 11, 7796-7804	5.6 20
307	Up regulation of Rho-associated coiled-coil containing kinase1 (ROCK1) is associated with genetic instability and poor prognosis in prostate cancer. <i>Aging</i> , 2019 , 11, 7859-7879	5.6 7
306	A nuclear shift of GSK3 β protein is an independent prognostic factor in prostate cancer. <i>Oncotarget</i> , 2019 , 10, 1729-1744	3.3 2
305	Nuclear ELAC2 overexpression is associated with increased hazard for relapse after radical prostatectomy. <i>Oncotarget</i> , 2019 , 10, 4973-4986	3.3 3
304	Prognostic and diagnostic role of PSA immunohistochemistry: A tissue microarray study on 21,000 normal and cancerous tissues. <i>Oncotarget</i> , 2019 , 10, 5439-5453	3.3 12
303	Nuclear up regulation of the BRCA1-associated ubiquitinase BAP1 is associated with tumor aggressiveness in prostate cancers lacking the TMPRSS2:ERG fusion. <i>Oncotarget</i> , 2019 , 10, 7096-7111	3.3 3
302	Upregulation of SPDEF is associated with poor prognosis in prostate cancer. <i>Oncology Letters</i> , 2019 , 18, 5107-5118	2.6 3
301	Prevalence of Syndecan-1 (CD138) Expression in Different Kinds of Human Tumors and Normal Tissues. <i>Disease Markers</i> , 2019 , 2019, 4928315	3.2 20
300	Loss of CCAAT-enhancer-binding protein alpha (CEBPA) is linked to poor prognosis in PTEN deleted and TMPRSS2:ERG fusion type prostate cancers. <i>Prostate</i> , 2019 , 79, 302-311	4.2 2
299	5q21 deletion is often heterogeneous in prostate cancer. <i>Genes Chromosomes and Cancer</i> , 2019 , 58, 509-515	5.15 3
298	Loss of PTEN-assisted G2/M checkpoint impedes homologous recombination repair and enhances radio-curability and PARP inhibitor treatment response in prostate cancer. <i>Scientific Reports</i> , 2018 , 8, 3947	4.9 37
297	EZH2 overexpression in head and neck cancer is related to lymph node metastasis. <i>Journal of Oral Pathology and Medicine</i> , 2018 , 47, 240-245	3.3 10
296	High BCAR1 expression is associated with early PSA recurrence in ERG negative prostate cancer. <i>BMC Cancer</i> , 2018 , 18, 37	4.8 14
295	Immunohistochemically detected IDH1 mutation is rare and mostly heterogeneous in prostate cancer. <i>World Journal of Urology</i> , 2018 , 36, 877-882	4 20

294	BCL2-overexpressing prostate cancer cells rely on PARP1-dependent end-joining and are sensitive to combined PARP inhibitor and radiation therapy. <i>Cancer Letters</i> , 2018 , 423, 60-70	9.9	16
293	Integrating Tertiary Gleason 5 Patterns into Quantitative Gleason Grading in Prostate Biopsies and Prostatectomy Specimens. <i>European Urology</i> , 2018 , 73, 674-683	10.2	32
292	13q deletion is linked to an adverse phenotype and poor prognosis in prostate cancer. <i>Genes Chromosomes and Cancer</i> , 2018 , 57, 504-512	5	22
291	PSCA expression is associated with favorable tumor features and reduced PSA recurrence in operated prostate cancer. <i>BMC Cancer</i> , 2018 , 18, 612	4.8	12
290	Marked Prognostic Impact of Minimal Lymphatic Tumor Spread in Prostate Cancer. <i>European Urology</i> , 2018 , 74, 376-386	10.2	40
289	IMP3 overexpression occurs in various important cancer types and is linked to aggressive tumor features: A tissue microarray study on 8,877 human cancers and normal tissues. <i>Oncology Reports</i> , 2018 , 39, 3-12	3.5	26
288	Abstract 696: Patterns of TIGIT expression in normal lymphatic tissue, inflammation and cancer 2018 ,		2
287	Upregulation of centromere protein F is linked to aggressive prostate cancers. <i>Cancer Management and Research</i> , 2018 , 10, 5491-5504	3.6	11
286	High expression of class III β tubulin in upper gastrointestinal cancer types. <i>Oncology Letters</i> , 2018 , 16, 7139-7145	2.6	7
285	Development and Characterization of a Spontaneously Metastatic Patient-Derived Xenograft Model of Human Prostate Cancer. <i>Scientific Reports</i> , 2018 , 8, 17535	4.9	14
284	Expression of the immune checkpoint receptor TIGIT in Hodgkin's lymphoma. <i>BMC Cancer</i> , 2018 , 18, 1202-8	4.8	14
283	Reduced RBM3 expression is associated with aggressive tumor features in esophageal cancer but not significantly linked to patient outcome. <i>BMC Cancer</i> , 2018 , 18, 1106	4.8	6
282	Deletion of 3p13 is a late event linked to progression of : fusion prostate cancer. <i>Cancer Management and Research</i> , 2018 , 10, 5909-5917	3.6	2
281	Molecular Evolution of Early-Onset Prostate Cancer Identifies Molecular Risk Markers and Clinical Trajectories. <i>Cancer Cell</i> , 2018 , 34, 996-1011.e8	24.3	89
280	High concordance of TMPRSS-ERG fusion between primary prostate cancer and its lymph node metastases. <i>Oncology Letters</i> , 2018 , 16, 6238-6244	2.6	3
279	Aberrant expression of membranous carbonic anhydrase IX (CAIX) is associated with unfavorable disease course in papillary and clear cell renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018 , 36, 531.e19-531.e25	2.8	9
278	Identification of a High-Level MET Amplification in CTCs and cfTNA of an ALK-Positive NSCLC Patient Developing Evasive Resistance to Crizotinib. <i>Journal of Thoracic Oncology</i> , 2018 , 13, e243-e246	8.9	15
277	Up regulation of the steroid hormone synthesis regulator HSD3B2 is linked to early PSA recurrence in prostate cancer. <i>Experimental and Molecular Pathology</i> , 2018 , 105, 50-56	4.4	5

276	βII-tubulin overexpression is linked to aggressive tumor features and genetic instability in urinary bladder cancer. <i>Human Pathology</i> , 2017 , 61, 210-220	3.7	15
275	MALDI imaging mass spectrometry reveals multiple clinically relevant masses in colorectal cancer using large-scale tissue microarrays. <i>Journal of Mass Spectrometry</i> , 2017 , 52, 165-173	2.2	17
274	Apurinic/apyrimidinic endonuclease 1 (APE1/Ref-1) overexpression is an independent prognostic marker in prostate cancer without TMPRSS2:ERG fusion. <i>Molecular Carcinogenesis</i> , 2017 , 56, 2135-2145	5	12
273	Overexpression of the A Disintegrin and Metalloproteinase ADAM15 is linked to a Small but Highly Aggressive Subset of Prostate Cancers. <i>Neoplasia</i> , 2017 , 19, 279-287	6.4	11
272	High concordance of findings obtained from transgluteal magnetic resonance imaging - and transrectal ultrasonography-guided biopsy as compared with prostatectomy specimens. <i>BJU International</i> , 2017 , 120, 365-376	5.6	2
271	The branched-chain amino acid transaminase 1 sustains growth of antiestrogen-resistant and ER-negative breast cancer. <i>Oncogene</i> , 2017 , 36, 4124-4134	9.2	41
270	THSD7A expression in human cancer. <i>Genes Chromosomes and Cancer</i> , 2017 , 56, 314-327	5	32
269	High-Level Glyoxalase 1 (GLO1) expression is linked to poor prognosis in prostate cancer. <i>Prostate</i> , 2017 , 77, 1528-1538	4.2	6
268	Prevalence of βII-tubulin (TUBB3) expression in human normal tissues and cancers. <i>Tumor Biology</i> , 2017 , 39, 1010428317712166	2.9	32
267	FOXA1 expression is a strong independent predictor of early PSA recurrence in ERG negative prostate cancers treated by radical prostatectomy. <i>Carcinogenesis</i> , 2017 , 38, 1180-1187	4.6	10
266	Increased ERCC1 expression is linked to chromosomal aberrations and adverse tumor biology in prostate cancer. <i>BMC Cancer</i> , 2017 , 17, 504	4.8	5
265	Up-regulation of Biglycan is Associated with Poor Prognosis and PTEN Deletion in Patients with Prostate Cancer. <i>Neoplasia</i> , 2017 , 19, 707-715	6.4	43
264	Mitochondrial mutations drive prostate cancer aggression. <i>Nature Communications</i> , 2017 , 8, 656	17.4	66
263	High-level βII-tubulin overexpression occurs in most head and neck cancers but is unrelated to clinical outcome. <i>Journal of Oral Pathology and Medicine</i> , 2017 , 46, 986-990	3.3	8
262	Up regulation and nuclear translocation of Y-box binding protein 1 (YB-1) is linked to poor prognosis in ERG-negative prostate cancer. <i>Scientific Reports</i> , 2017 , 7, 2056	4.9	23
261	Up-regulation of mismatch repair genes MSH6, PMS2 and MLH1 parallels development of genetic instability and is linked to tumor aggressiveness and early PSA recurrence in prostate cancer. <i>Carcinogenesis</i> , 2017 , 38, 19-27	4.6	29
260	Quantification of telomere features in tumor tissue sections by an automated 3D imaging-based workflow. <i>Methods</i> , 2017 , 114, 60-73	4.6	10
259	CD151 expression is frequent but unrelated to clinical outcome in head and neck cancer. <i>Clinical Oral Investigations</i> , 2017 , 21, 1503-1508	4.2	1

258	High-Level β -Glutamyl-Hydrolase (GGH) Expression is Linked to Poor Prognosis in ERG Negative Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	15
257	Deletion of 8p is an independent prognostic parameter in prostate cancer. <i>Oncotarget</i> , 2017 , 8, 379-392	3.3	30
256	Family with sequence similarity 13C (FAM13C) overexpression is an independent prognostic marker in prostate cancer. <i>Oncotarget</i> , 2017 , 8, 31494-31508	3.3	3
255	PTEN loss detection in prostate cancer: comparison of PTEN immunohistochemistry and PTEN FISH in a large retrospective prostatectomy cohort. <i>Oncotarget</i> , 2017 , 8, 65566-65576	3.3	35
254	Deletion lengthening at chromosomes 6q and 16q targets multiple tumor suppressor genes and is associated with an increasingly poor prognosis in prostate cancer. <i>Oncotarget</i> , 2017 , 8, 108923-108935	3.3	21
253	High Ki67 expression is an independent good prognostic marker in colorectal cancer. <i>Journal of Clinical Pathology</i> , 2016 , 69, 209-14	3.9	71
252	Cyclin D1 gene amplification is highly homogeneous in breast cancer. <i>Breast Cancer</i> , 2016 , 23, 111-119	3.4	28
251	Loss of membranous VEGFR1 expression is associated with an adverse phenotype and shortened survival in breast cancer. <i>Molecular Medicine Reports</i> , 2016 , 14, 1443-50	2.9	5
250	p16 upregulation is linked to poor prognosis in ERG negative prostate cancer. <i>Tumor Biology</i> , 2016 , 37, 12655-12663	2.9	16
249	Internationales Krebsgenomkonsortium (ICGC). <i>Medizinische Genetik</i> , 2016 , 28, 416-423	0.5	
248	Heterogeneity of ERG expression in prostate cancer: a large section mapping study of entire prostatectomy specimens from 125 patients. <i>BMC Cancer</i> , 2016 , 16, 641	4.8	19
247	Reduced AZGP1 expression is an independent predictor of early PSA recurrence and associated with ERG-fusion positive and PTEN deleted prostate cancers. <i>International Journal of Cancer</i> , 2016 , 138, 1199-206	7.5	21
246	Internal standardization of LA-ICP-MS immuno imaging via printing of universal metal spiked inks onto tissue sections. <i>Journal of Analytical Atomic Spectrometry</i> , 2016 , 31, 801-808	3.7	21
245	Epidermal growth factor receptor overexpression is common and not correlated to gene copy number in ependymoma. <i>Childs Nervous System</i> , 2016 , 32, 281-90	1.7	4
244	Loss of H2Bub1 Expression is Linked to Poor Prognosis in Nodal Negative Colorectal Cancers. <i>Pathology and Oncology Research</i> , 2016 , 22, 95-102	2.6	15
243	Clinical Utility of Quantitative Gleason Grading in Prostate Biopsies and Prostatectomy Specimens. <i>European Urology</i> , 2016 , 69, 592-598	10.2	167
242	Aquaporin 5 expression is frequent in prostate cancer and shows a dichotomous correlation with tumor phenotype and PSA recurrence. <i>Human Pathology</i> , 2016 , 48, 102-10	3.7	13
241	p16 overexpression and 9p21 deletion are linked to unfavorable tumor phenotype in breast cancer. <i>Oncotarget</i> , 2016 , 7, 81322-81331	3.3	24

240	Deletion of 18q is a strong and independent prognostic feature in prostate cancer. <i>Oncotarget</i> , 2016 , 7, 86339-86349	3.3	23
239	Heterogeneity and chronology of 6q15 deletion and ERG-fusion in prostate cancer. <i>Oncotarget</i> , 2016 , 7, 3897-904	3.3	6
238	Tissue Microarrays. <i>Methods in Molecular Biology</i> , 2016 , 1381, 53-65	1.4	18
237	Loss of RNA-binding motif protein 3 expression is associated with right-sided localization and poor prognosis in colorectal cancer. <i>Histopathology</i> , 2016 , 68, 191-8	7.3	18
236	Cytoplasmic accumulation of ELAVL1 is an independent predictor of biochemical recurrence associated with genomic instability in prostate cancer. <i>Prostate</i> , 2016 , 76, 259-72	4.2	18
235	Diverse expression patterns of the EMT suppressor grainyhead-like 2 (GRHL2) in normal and tumour tissues. <i>International Journal of Cancer</i> , 2016 , 138, 949-63	7.5	16
234	High levels of class III β tubulin expression are associated with aggressive tumor features in breast cancer. <i>Oncology Letters</i> , 2016 , 11, 1987-1994	2.6	28
233	The Combination of DNA Ploidy Status and PTEN/6q15 Deletions Provides Strong and Independent Prognostic Information in Prostate Cancer. <i>Clinical Cancer Research</i> , 2016 , 22, 2802-11	12.9	13
232	Loss of CHD1 causes DNA repair defects and enhances prostate cancer therapeutic responsiveness. <i>EMBO Reports</i> , 2016 , 17, 1609-1623	6.5	58
231	Reprogramming of the ER α and ER β target gene landscape triggers tamoxifen resistance in breast cancer. <i>Cancer Research</i> , 2015 , 75, 720-31	10.1	32
230	β II-tubulin overexpression is linked to aggressive tumor features and shortened survival in clear cell renal cell carcinoma. <i>World Journal of Urology</i> , 2015 , 33, 1561-9	4	10
229	Heterogeneity of amplification of HER2, EGFR, CCND1 and MYC in gastric cancer. <i>BMC Gastroenterology</i> , 2015 , 15, 7	3	82
228	VEGFR-1 overexpression identifies a small subgroup of aggressive prostate cancers in patients treated by prostatectomy. <i>International Journal of Molecular Sciences</i> , 2015 , 16, 8591-606	6.3	3
227	HDAC1 overexpression independently predicts biochemical recurrence and is associated with rapid tumor cell proliferation and genomic instability in prostate cancer. <i>Experimental and Molecular Pathology</i> , 2015 , 98, 419-26	4.4	20
226	<i>Saccharomyces cerevisiae</i> -like 1 overexpression is frequent in prostate cancer and has markedly different effects in Ets-related gene fusion-positive and fusion-negative cancers. <i>Human Pathology</i> , 2015 , 46, 514-23	3.7	7
225	Overexpression of enhancer of zeste homolog 2 (EZH2) characterizes an aggressive subset of prostate cancers and predicts patient prognosis independently from pre- and postoperatively assessed clinicopathological parameters. <i>Carcinogenesis</i> , 2015 , 36, 1333-40	4.6	37
224	The Molecular Taxonomy of Primary Prostate Cancer. <i>Cell</i> , 2015 , 163, 1011-25	56.2	1713
223	β II-tubulin overexpression is linked to left-sided tumor localization and nuclear β catenin expression in colorectal cancer. <i>Cancer Treatment Communications</i> , 2015 , 4, 96-102		

222	8p deletion is strongly linked to poor prognosis in breast cancer. <i>Cancer Biology and Therapy</i> , 2015 , 16, 1080-7	4.6	20
221	The prognostic value of SUMO1/Sentrin specific peptidase 1 (SEN1) in prostate cancer is limited to ERG-fusion positive tumors lacking PTEN deletion. <i>BMC Cancer</i> , 2015 , 15, 538	4.8	27
220	Cytoplasmic Accumulation of Sequestosome 1 (p62) Is a Predictor of Biochemical Recurrence, Rapid Tumor Cell Proliferation, and Genomic Instability in Prostate Cancer. <i>Clinical Cancer Research</i> , 2015 , 21, 3471-9	12.9	36
219	BAZ2A (TIP5) is involved in epigenetic alterations in prostate cancer and its overexpression predicts disease recurrence. <i>Nature Genetics</i> , 2015 , 47, 22-30	36.3	99
218	PSMA expression is highly homogenous in primary prostate cancer. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2015 , 23, 449-55	1.9	19
217	Concurrent deletion of 16q23 and PTEN is an independent prognostic feature in prostate cancer. <i>International Journal of Cancer</i> , 2015 , 137, 2354-63	7.5	33
216	Partial PTEN deletion is linked to poor prognosis in breast cancer. <i>BMC Cancer</i> , 2015 , 15, 963	4.8	27
215	Cdc7 overexpression is an independent prognostic marker and a potential therapeutic target in colorectal cancer. <i>Diagnostic Pathology</i> , 2015 , 10, 125	3	16
214	Loss of SOX9 Expression Is Associated with PSA Recurrence in ERG-Positive and PTEN Deleted Prostate Cancers. <i>PLoS ONE</i> , 2015 , 10, e0128525	3.7	24
213	High-Level HOOK3 Expression Is an Independent Predictor of Poor Prognosis Associated with Genomic Instability in Prostate Cancer. <i>PLoS ONE</i> , 2015 , 10, e0134614	3.7	8
212	HOXB13 overexpression is an independent predictor of early PSA recurrence in prostate cancer treated by radical prostatectomy. <i>Oncotarget</i> , 2015 , 6, 12822-34	3.3	26
211	Determination of Tumor Heterogeneity in Colorectal Cancers Using Heterogeneity Tissue Microarrays. <i>Pathology and Oncology Research</i> , 2015 , 21, 1183-9	2.6	6
210	Prevalence of chromosomal rearrangements involving non-ETS genes in prostate cancer. <i>International Journal of Oncology</i> , 2015 , 46, 1637-42	4.4	9
209	Expression of DNA ligase IV is linked to poor prognosis and characterizes a subset of prostate cancers harboring TMPRSS2:ERG fusion and PTEN deletion. <i>Oncology Reports</i> , 2015 , 34, 1211-20	3.5	6
208	FGFR1 Amplification Is Often Homogeneous and Strongly Linked to the Squamous Cell Carcinoma Subtype in Esophageal Carcinoma. <i>PLoS ONE</i> , 2015 , 10, e0141867	3.7	13
207	Overexpression of thymidylate synthase (TYMS) is associated with aggressive tumor features and early PSA recurrence in prostate cancer. <i>Oncotarget</i> , 2015 , 6, 8377-87	3.3	33
206	Expression of phospho-mTOR kinase is abundant in colorectal cancer and associated with left-sided tumor localization. <i>International Journal of Clinical and Experimental Pathology</i> , 2015 , 8, 7009-15	1.4	7
205	High intratumoral FOXP3+ T regulatory cell (Tregs) density is an independent good prognosticator in nodal negative colorectal cancer. <i>International Journal of Clinical and Experimental Pathology</i> , 2015 , 8, 8227-35	1.4	24

204	Genomic deletion of chromosome 12p is an independent prognostic marker in prostate cancer. <i>Oncotarget</i> , 2015 , 6, 27966-79	3.3	28
203	The combination of DNA ploidy status and PTEN/6q15 deletions to provide strong and independent prognostic information in prostate cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 5027-5027 ²		
202	βII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion. <i>American Journal of Pathology</i> , 2014 , 184, 609-17	5.8	44
201	NY-ESO-1 expression is tightly linked to TMPRSS2-ERG fusion in prostate cancer. <i>Prostate</i> , 2014 , 74, 1012-22	4.2	9
200	Immunohistochemical and FISH analysis of EGFR and its prognostic value in patients with oral squamous cell carcinoma. <i>Journal of Oral Pathology and Medicine</i> , 2014 , 43, 205-10	3.3	24
199	High RNA-binding motif protein 3 expression is an independent prognostic marker in operated prostate cancer and tightly linked to ERG activation and PTEN deletions. <i>European Journal of Cancer</i> , 2014 , 50, 852-61	7.5	33
198	TMPRSS2-ERG fusions are strongly linked to young patient age in low-grade prostate cancer. <i>European Urology</i> , 2014 , 66, 978-81	10.2	48
197	Intratumor DNA methylation heterogeneity reflects clonal evolution in aggressive prostate cancer. <i>Cell Reports</i> , 2014 , 8, 798-806	10.6	177
196	Endometrial Carcinoma Recurrence Score (ECARS) validates to identify aggressive disease and associates with markers of epithelial-mesenchymal transition and PI3K alterations. <i>Gynecologic Oncology</i> , 2014 , 134, 599-606	4.9	8
195	Reduced membranous MET expression is linked to bladder cancer progression. <i>Cancer Genetics</i> , 2014 , 207, 147-52	2.3	4
194	P53 immunohistochemical expression does not correlate with clinical features in 207 carcinomas of the oral cavity and in the head and neck region. <i>Clinical Oral Investigations</i> , 2014 , 18, 211-7	4.2	6
193	Patterns of TPD52 overexpression in multiple human solid tumor types analyzed by quantitative PCR. <i>International Journal of Oncology</i> , 2014 , 44, 609-15	4.4	22
192	Loss of ALCAM expression is linked to adverse phenotype and poor prognosis in breast cancer: a TMA-based immunohistochemical study on 2,197 breast cancer patients. <i>Oncology Reports</i> , 2014 , 32, 2628-34	3.5	16
191	The multifunctional growth factor midkine promotes proliferation and migration in pancreatic cancer. <i>Molecular Cancer Research</i> , 2014 , 12, 670-80	6.6	29
190	Patterns of ALK expression in different human cancer types. <i>Journal of Clinical Pathology</i> , 2014 , 67, 477-81	3.1	5
189	High nuclear karyopherin β expression is a strong and independent predictor of biochemical recurrence in prostate cancer patients treated by radical prostatectomy. <i>Modern Pathology</i> , 2014 , 27, 96-106	9.8	24
188	The prognostic impact of high Nijmegen breakage syndrome (NBS1) gene expression in ERG-negative prostate cancers lacking PTEN deletion is driven by KPNA2 expression. <i>International Journal of Cancer</i> , 2014 , 135, 1399-407	7.5	29
187	Heterogeneity and chronology of PTEN deletion and ERG fusion in prostate cancer. <i>Modern Pathology</i> , 2014 , 27, 1612-20	9.8	59

186	MALDI imaging-based identification of prognostically relevant signals in bladder cancer using large-scale tissue microarrays. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 1225-33 ^{2.8}	24
185	Clinical significance of different types of p53 gene alteration in surgically treated prostate cancer. <i>International Journal of Cancer</i> , 2014 , 135, 1369-80	7.5 85
184	FISH Oracle 2: a web server for integrative visualization of genomic data in cancer research. <i>Journal of Clinical Bioinformatics</i> , 2014 , 4, 5	5
183	Aberrant presentation of HPA-reactive carbohydrates implies Selectin-independent metastasis formation in human prostate cancer. <i>Clinical Cancer Research</i> , 2014 , 20, 1791-802	12.9 23
182	Qualitative and Quantitative Requirements for Assessing Prognostic Markers in Prostate Cancer. <i>Microarrays (Basel, Switzerland)</i> , 2014 , 3, 137-58	2
181	CCND1 amplification and cyclin D1 immunohistochemical expression in head and neck squamous cell carcinomas. <i>Clinical Oral Investigations</i> , 2014 , 18, 269-76	4.2 37
180	MALDI imaging on tissue microarrays identifies molecular features associated with renal cell cancer phenotype. <i>Anticancer Research</i> , 2014 , 34, 2255-61	2.3 27
179	Recurrent deletion of 3p13 targets multiple tumour suppressor genes and defines a distinct subgroup of aggressive ERG fusion-positive prostate cancers. <i>Journal of Pathology</i> , 2013 , 231, 130-41	9.4 112
178	Presence of the coxsackievirus and adenovirus receptor (CAR) in human neoplasms: a multitumour array analysis. <i>British Journal of Cancer</i> , 2013 , 109, 1848-58	8.7 37
177	SPINK1 expression is tightly linked to 6q15- and 5q21-deleted ERG-fusion negative prostate cancers but unrelated to PSA recurrence. <i>Prostate</i> , 2013 , 73, 1690-8	4.2 34
176	Overexpression of the chromatin remodeler death-domain-associated protein in prostate cancer is an independent predictor of early prostate-specific antigen recurrence. <i>Human Pathology</i> , 2013 , 44, 1789-96	17
175	High mitochondria content is associated with prostate cancer disease progression. <i>Molecular Cancer</i> , 2013 , 12, 145	42.1 39
174	Prognostic relevance of AIB1 (NCoA3) amplification and overexpression in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013 , 137, 745-53	4.4 34
173	Altered PTEN function caused by deletion or gene disruption is associated with poor prognosis in rectal but not in colon cancer. <i>Human Pathology</i> , 2013 , 44, 1524-33	3.7 17
172	High lysophosphatidylcholine acyltransferase 1 expression independently predicts high risk for biochemical recurrence in prostate cancers. <i>Molecular Oncology</i> , 2013 , 7, 1001-11	7.9 40
171	High tissue density of FOXP3+ T cells is associated with clinical outcome in prostate cancer. <i>European Journal of Cancer</i> , 2013 , 49, 1273-9	7.5 83
170	Reduced CD147 expression is linked to ERG fusion-positive prostate cancers but lacks substantial impact on PSA recurrence in patients treated by radical prostatectomy. <i>Experimental and Molecular Pathology</i> , 2013 , 95, 227-34	4.4 13
169	Amplification of the PPFIA1 gene region on 11q13 in oral squamous cell carcinomas (OSCC). <i>Journal of Cranio-Maxillo-Facial Surgery</i> , 2013 , 41, 845-9	3.6 13

168	Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. <i>Cancer Cell</i> , 2013 , 23, 159-70	24.3	259
167	RAD51 overexpression is a negative prognostic marker for colorectal adenocarcinoma. <i>International Journal of Cancer</i> , 2013 , 132, 2118-26	7.5	75
166	MALDI imaging on large-scale tissue microarrays identifies molecular features associated with tumour phenotype in oesophageal cancer. <i>Histopathology</i> , 2013 , 63, 455-62	7.3	18
165	PTEN deletions are related to disease progression and unfavourable prognosis in early bladder cancer. <i>Histopathology</i> , 2013 , 63, 670-7	7.3	19
164	Frequent intratumoral heterogeneity of EGFR gene copy gain in non-small cell lung cancer. <i>Lung Cancer</i> , 2013 , 79, 221-7	5.9	14
163	Loss of pSer2448-mTOR expression is linked to adverse prognosis and tumor progression in ERG-fusion-positive cancers. <i>International Journal of Cancer</i> , 2013 , 132, 1333-40	7.5	32
162	Cysteine-rich secretory protein 3 overexpression is linked to a subset of PTEN-deleted ERG fusion-positive prostate cancers with early biochemical recurrence. <i>Modern Pathology</i> , 2013 , 26, 733-42	9.8	32
161	Genomic deletion of MAP3K7 at 6q12-22 is associated with early PSA recurrence in prostate cancer and absence of TMPRSS2:ERG fusions. <i>Modern Pathology</i> , 2013 , 26, 975-83	9.8	121
160	Marked heterogeneity of ERG expression in large primary prostate cancers. <i>Modern Pathology</i> , 2013 , 26, 106-16	9.8	56
159	Loss of CDKN1B/p27Kip1 expression is associated with ERG fusion-negative prostate cancer, but is unrelated to patient prognosis. <i>Oncology Letters</i> , 2013 , 6, 1245-1252	2.6	18
158	High phospho-Stathmin(Serine38) expression identifies aggressive endometrial cancer and suggests an association with PI3K inhibition. <i>Clinical Cancer Research</i> , 2013 , 19, 2331-41	12.9	33
157	CHD1 is a 5q21 tumor suppressor required for ERG rearrangement in prostate cancer. <i>Cancer Research</i> , 2013 , 73, 2795-805	10.1	169
156	Strong expression of the neuronal transcription factor FOXP2 is linked to an increased risk of early PSA recurrence in ERG fusion-negative cancers. <i>Journal of Clinical Pathology</i> , 2013 , 66, 563-8	3.9	25
155	HER2 amplification in squamous cell carcinomas of the vulva. <i>Histopathology</i> , 2013 , 62, 965-7	7.3	2
154	MALDI mass spectrometric imaging based identification of clinically relevant signals in prostate cancer using large-scale tissue microarrays. <i>International Journal of Cancer</i> , 2013 , 133, 920-8	7.5	47
153	Immunohistochemical analysis of p16 expression, HPV infection and its prognostic utility in oral squamous cell carcinoma. <i>Journal of Oral Pathology and Medicine</i> , 2013 , 42, 676-81	3.3	22
152	High Nr-CAM expression is associated with favorable phenotype and late PSA recurrence in prostate cancer treated by prostatectomy. <i>Prostate Cancer and Prostatic Diseases</i> , 2013 , 16, 159-64	6.2	6
151	High c-MET expression is frequent but not associated with early PSA recurrence in prostate cancer. <i>Experimental and Therapeutic Medicine</i> , 2013 , 5, 102-106	2.1	12

150	Integrated genomic analysis of the 8q24 amplification in endometrial cancers identifies ATAD2 as essential to MYC-dependent cancers. <i>PLoS ONE</i> , 2013 , 8, e54873	3.7	56
149	ESR1 amplification in breast cancer by optimized RNase FISH: frequent but low-level and heterogeneous. <i>PLoS ONE</i> , 2013 , 8, e84189	3.7	13
148	Intratumoral T but not B lymphocytes are related to clinical outcome in prostate cancer. <i>Apmis</i> , 2012 , 120, 901-8	3.4	57
147	Epidermal growth factor receptor protein expression and genomic alterations in renal cell carcinoma. <i>Cancer</i> , 2012 , 118, 1268-75	6.4	43
146	BIRC2 amplification in squamous cell carcinomas of the uterine cervix. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2012 , 461, 123-8	5.1	12
145	PTEN deletion is rare but often homogeneous in gastric cancer. <i>Journal of Clinical Pathology</i> , 2012 , 65, 693-8	3.9	15
144	KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer. <i>British Journal of Cancer</i> , 2012 , 107, 1997-2004	8.7	52
143	Genome-wide DNA methylation events in TMPRSS2-ERG fusion-negative prostate cancers implicate an EZH2-dependent mechanism with miR-26a hypermethylation. <i>Cancer Discovery</i> , 2012 , 2, 1024-35	24.4	107
142	Role of cyclin D1 amplification and expression in vulvar carcinomas. <i>Human Pathology</i> , 2012 , 43, 1386-93	3.7	13
141	Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer. <i>American Journal of Pathology</i> , 2012 , 181, 401-12	5.8	256
140	Y chromosome losses are exceedingly rare in prostate cancer and unrelated to patient age. <i>Prostate</i> , 2012 , 72, 898-903	4.2	7
139	Prognostic relevance of Bcl-2 overexpression in surgically treated prostate cancer is not caused by increased copy number or translocation of the gene. <i>Prostate</i> , 2012 , 72, 991-7	4.2	26
138	Loss of protein expression and recurrent DNA hypermethylation of the GNG7 gene in squamous cell carcinoma of the head and neck. <i>Journal of Applied Genetics</i> , 2012 , 53, 167-74	2.5	23
137	On the evidence for ESR1 amplification in breast cancer. <i>Nature Reviews Cancer</i> , 2012 , 12, 149	31.3	14
136	The impact of the number of cores on tissue microarray studies investigating prostate cancer biomarkers. <i>International Journal of Oncology</i> , 2012 , 40, 261-8	4.4	21
135	Self downregulation by Ras causes MEK1/2 to become aberrantly nuclear localized leading to polyploidy and neoplastic transformation. <i>Cancer Research</i> , 2012 , 72, 626-35	10.1	34
134	EGFR gene copy number increase in vulvar carcinomas is linked with poor clinical outcome. <i>Journal of Clinical Pathology</i> , 2012 , 65, 133-9	3.9	24
133	Heterogeneity of ERBB2 amplification in adenocarcinoma, squamous cell carcinoma and large cell undifferentiated carcinoma of the lung. <i>Modern Pathology</i> , 2012 , 25, 1566-73	9.8	37

132	Reduced CD151 expression is related to advanced tumour stage in urothelial bladder cancer. <i>Pathology</i> , 2012 , 44, 448-52	1.6	10
131	Estrogen receptor alpha (ESR1) gene amplification status and clinical outcome in tamoxifen-treated postmenopausal patients with endocrine-responsive early breast cancer: An analysis of the prospective ABCSG-6 trial.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 10501-10501	2.2	3
130	Immunoexpression analysis and prognostic value of BLCAP in breast cancer. <i>PLoS ONE</i> , 2012 , 7, e45967	3.7	7
129	Association of nuclear accumulation of p53 with ERG fusion and poor prognosis in prostate cancer.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 124-124	2.2	
128	HER-2 discordance between primary gastric carcinoma and paired lymph node metastasis - reply. <i>Human Pathology</i> , 2011 , 42, 910-911	3.7	1
127	No detection of XMRV in blood samples and tissue sections from prostate cancer patients in Northern Europe. <i>PLoS ONE</i> , 2011 , 6, e25592	3.7	17
126	Role of TP53 mutations in vulvar carcinomas. <i>International Journal of Gynecological Pathology</i> , 2011 , 30, 497-504	3.2	41
125	The relationship between annual hospital volume of trauma patients and in-hospital mortality in New York State. <i>Journal of Trauma</i> , 2011 , 71, 339-45; discussion 345-6		28
124	Miliary never-smoking adenocarcinoma of the lung: strong association with epidermal growth factor receptor exon 19 deletion. <i>Journal of Thoracic Oncology</i> , 2011 , 6, 199-202	8.9	44
123	FISH Oracle: a web server for flexible visualization of DNA copy number data in a genomic context. <i>Journal of Clinical Bioinformatics</i> , 2011 , 1, 20		12
122	Serum midkine correlates with tumor progression and imatinib response in gastrointestinal stromal tumors. <i>Annals of Surgical Oncology</i> , 2011 , 18, 559-65	3.1	16
121	Overexpression of carbonic anhydrase IX (CAIX) is an independent unfavorable prognostic marker in endometrioid ovarian cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2011 , 459, 193-200	5.1	57
120	TMPRSS2-ERG -specific transcriptional modulation is associated with prostate cancer biomarkers and TGF- β signaling. <i>BMC Cancer</i> , 2011 , 11, 507	4.8	117
119	High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer. <i>Prostate</i> , 2011 , 71, 281-8	4.2	179
118	MMSET is highly expressed and associated with aggressiveness in neuroblastoma. <i>Cancer Research</i> , 2011 , 71, 4226-35	10.1	51
117	The histone methyltransferase and putative oncoprotein MMSET is overexpressed in a large variety of human tumors. <i>Clinical Cancer Research</i> , 2011 , 17, 2919-33	12.9	106
116	ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy. <i>Clinical Cancer Research</i> , 2011 , 17, 5878-88	12.9	225
115	Targeting activin receptor-like kinase 1 inhibits angiogenesis and tumorigenesis through a mechanism of action complementary to anti-VEGF therapies. <i>Cancer Research</i> , 2011 , 71, 1362-73	10.1	98

114	SCRIB expression is deregulated in human prostate cancer, and its deficiency in mice promotes prostate neoplasia. <i>Journal of Clinical Investigation</i> , 2011 , 121, 4257-67	15.9	131
113	MDM2 amplification is an independent prognostic feature of node-negative, estrogen receptor-positive early-stage breast cancer. <i>Cancer Biomarkers</i> , 2010 , 8, 53-60	3.8	20
112	Homogeneous EGFR amplification defines a subset of aggressive Barrett's adenocarcinomas with poor prognosis. <i>Histopathology</i> , 2010 , 57, 418-26	7.3	26
111	Activating BRAF gene mutations are uncommon in hormone refractory prostate cancer in Caucasian patients. <i>Oncology Letters</i> , 2010 , 1, 729-732	2.6	14
110	Chromosome 8p deletions and 8q gains are associated with tumor progression and poor prognosis in prostate cancer. <i>Clinical Cancer Research</i> , 2010 , 16, 56-64	12.9	98
109	Low level HER2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer. <i>Clinical Cancer Research</i> , 2010 , 16, 1553-60	12.9	113
108	Y chromosome loss is a frequent early event in urothelial bladder cancer. <i>Pathology</i> , 2010 , 42, 356-9	1.6	28
107	Bladder cancer-associated protein, a potential prognostic biomarker in human bladder cancer. <i>Molecular and Cellular Proteomics</i> , 2010 , 9, 161-77	7.6	37
106	Amplification of 8q21 in breast cancer is independent of MYC and associated with poor patient outcome. <i>Modern Pathology</i> , 2010 , 23, 603-10	9.8	27
105	Proteomic profiling of mammary carcinomas identifies C7orf24, a gamma-glutamyl cyclotransferase, as a potential cancer biomarker. <i>Journal of Proteome Research</i> , 2010 , 9, 3941-53	5.6	46
104	Overexpression of cell division cycle 7 homolog is associated with gene amplification frequency in breast cancer. <i>Human Pathology</i> , 2010 , 41, 358-65	3.7	30
103	HER-2 amplification is highly homogenous in gastric cancer. <i>Human Pathology</i> , 2010 , 41, 305-306	3.7	10
102	Heterogenous high-level HER-2 amplification in a small subset of colorectal cancers. <i>Human Pathology</i> , 2010 , 41, 1577-85	3.7	61
101	Loss of reelin expression in breast cancer is epigenetically controlled and associated with poor prognosis. <i>American Journal of Pathology</i> , 2010 , 177, 2323-33	5.8	48
100	Overexpression of carbonic anhydrase IX (CAIX) in vulvar cancer is associated with tumor progression and development of locoregional lymph node metastases. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2010 , 456, 483-90	5.1	17
99	Gene amplification in ductal carcinoma in situ of the breast. <i>Breast Cancer Research and Treatment</i> , 2010 , 123, 757-65	4.4	58
98	Establishment and characterization of a new human pancreatic adenocarcinoma cell line with high metastatic potential to the lung. <i>BMC Cancer</i> , 2010 , 10, 295	4.8	34
97	PPF1A1 and CCND1 are frequently coamplified in breast cancer. <i>Genes Chromosomes and Cancer</i> , 2010 , 49, 1-8	5	16

96	19q13 amplification is associated with high grade and stage in pancreatic cancer. <i>Genes Chromosomes and Cancer</i> , 2010 , 49, 569-75	5	17
95	Pitfalls in mutational testing and reporting of common KIT and PDGFRA mutations in gastrointestinal stromal tumors. <i>BMC Medical Genetics</i> , 2010 , 11, 106	2.1	22
94	Tissue microarrays. <i>Methods in Molecular Biology</i> , 2010 , 576, 49-60	1.4	23
93	Applications of tissue microarray technology. <i>Methods in Molecular Biology</i> , 2010 , 664, 1-16	1.4	15
92	Immunohistochemical analysis of tissue microarrays. <i>Methods in Molecular Biology</i> , 2010 , 664, 113-26	1.4	52
91	Recipient block TMA technique. <i>Methods in Molecular Biology</i> , 2010 , 664, 37-44	1.4	60
90	HER-2/neu analysis in breast cancer bone metastases. <i>Journal of Clinical Pathology</i> , 2009 , 62, 542-6	3.9	13
89	Molecular cancer phenotype in normal prostate tissue. <i>European Urology</i> , 2009 , 55, 885-90	10.2	21
88	Immunological microenvironment in prostate cancer: high mast cell densities are associated with favorable tumor characteristics and good prognosis. <i>Prostate</i> , 2009 , 69, 976-81	4.2	100
87	Estrogen receptor gene amplification occurs rarely in ovarian cancer. <i>Modern Pathology</i> , 2009 , 22, 191-6	9.8	12
86	Impaired gastric acidification negatively affects calcium homeostasis and bone mass. <i>Nature Medicine</i> , 2009 , 15, 674-81	50.5	133
85	Combined alpha-methylacyl coenzyme A racemase/p53 analysis to identify dysplasia in inflammatory bowel disease. <i>Human Pathology</i> , 2009 , 40, 166-73	3.7	26
84	HER-2 amplification is highly homogenous in gastric cancer. <i>Human Pathology</i> , 2009 , 40, 769-77	3.7	176
83	Clinical significance of p53 alterations in surgically treated prostate cancers. <i>Modern Pathology</i> , 2008 , 21, 1371-8	9.8	165
82	Reply to ESR1 gene amplification in breast cancer: a common phenomenon? <i>Nature Genetics</i> , 2008 , 40, 810-812	36.3	41
81	Marked gene transcript level alterations occur early during radical prostatectomy. <i>European Urology</i> , 2008 , 53, 333-44	10.2	31
80	Expression and prognostic relevance of annexin A3 in prostate cancer. <i>European Urology</i> , 2008 , 54, 1314-22	12.2	82
79	The apoptosis linked gene ALG-2 is dysregulated in tumors of various origin and contributes to cancer cell viability. <i>Molecular Oncology</i> , 2008 , 1, 431-9	7.9	41

78	Distinct gene expression profiles: nodal versus extranodal diffuse large B-cell lymphoma. <i>Oncology</i> , 2008 , 75, 71-80	3.6	17
77	Distinct subcellular expression patterns of neutral endopeptidase (CD10) in prostate cancer predict diverging clinical courses in surgically treated patients. <i>Clinical Cancer Research</i> , 2008 , 14, 7838-42	12.9	55
76	AMACR expression in colorectal cancer is associated with left-sided tumor localization. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2008 , 453, 243-8	5.1	28
75	Oestrogen receptor gene (ESR1) amplification is frequent in endometrial carcinoma and its precursor lesions. <i>Journal of Pathology</i> , 2008 , 216, 151-7	9.4	29
74	Frequent loss of SFRP1 expression in multiple human solid tumours: association with aberrant promoter methylation in renal cell carcinoma. <i>Oncogene</i> , 2007 , 26, 5680-91	9.2	118
73	Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. <i>Modern Pathology</i> , 2007 , 20, 120-9	9.8	154
72	Close association between HER-2 amplification and overexpression in human tumors of non-breast origin. <i>Modern Pathology</i> , 2007 , 20, 192-8	9.8	49
71	HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer. <i>Journal of Clinical Pathology</i> , 2007 , 60, 768-72	3.9	90
70	Clinical significance of epidermal growth factor receptor protein overexpression and gene copy number gains in prostate cancer. <i>Clinical Cancer Research</i> , 2007 , 13, 6579-84	12.9	128
69	Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer. <i>Nature Genetics</i> , 2007 , 39, 655-60	36.3	291
68	Decay-accelerating factor (CD55): a versatile acting molecule in human malignancies. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2006 , 1766, 42-52	11.2	23
67	Tissue microarrays for comparing molecular features with proliferation activity in breast cancer. <i>International Journal of Cancer</i> , 2006 , 118, 2190-4	7.5	96
66	Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates. <i>Cancer Research</i> , 2006 , 66, 2328-37	10.1	123
65	Microsatellite DNA alterations of gastrointestinal stromal tumors are predictive for outcome. <i>Clinical Cancer Research</i> , 2006 , 12, 5151-7	12.9	20
64	Epstein-Barr virus infection is not the sole cause of high prevalence for Hodgkin's lymphoma in Saudi Arabia. <i>Leukemia and Lymphoma</i> , 2006 , 47, 707-13	1.9	11
63	Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. <i>British Journal of Cancer</i> , 2006 , 94, 128-35	8.7	291
62	High epidermal growth factor receptor amplification rate but low mutation frequency in Middle East lung cancer population. <i>Human Pathology</i> , 2006 , 37, 453-7	3.7	20
61	High frequency and strong prognostic relevance of O6-methylguanine DNA methyltransferase silencing in diffuse large B-cell lymphomas from the Middle East. <i>Human Pathology</i> , 2006 , 37, 742-8	3.7	14

60	The expression and action of decay-accelerating factor (CD55) in human malignancies and cancer therapy. <i>Analytical Cellular Pathology</i> , 2006 , 28, 223-32	3.4	17
59	High throughput tissue microarray analysis of FHIT expression in diffuse large cell B-cell lymphoma from Saudi Arabia. <i>Modern Pathology</i> , 2006 , 19, 1124-9	9.8	5
58	E2F3 is the main target gene of the 6p22 amplicon with high specificity for human bladder cancer. <i>Oncogene</i> , 2006 , 25, 6538-43	9.2	37
57	The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study. <i>Breast Cancer Research and Treatment</i> , 2006 , 97, 275-83	4.4	176
56	Colorectal carcinoma from Saudi Arabia. Analysis of MLH-1, MSH-2 and p53 genes by immunohistochemistry and tissue microarray analysis. <i>Journal of King Abdulaziz University, Islamic Economics</i> , 2006 , 27, 323-8	1.1	9
55	High-throughput tissue microarray analysis of COX2 expression in urinary bladder cancer 2005 , 27, 385		1
54	Selective expression of a splice variant of decay-accelerating factor in c-erbB-2-positive mammary carcinoma cells showing increased transendothelial invasiveness. <i>Biochemical and Biophysical Research Communications</i> , 2005 , 329, 318-23	3.4	5
53	Predominance of high-grade pathway in breast cancer development of Middle East women. <i>Modern Pathology</i> , 2005 , 18, 891-7	9.8	51
52	High-throughput tissue microarray analysis of CMYC amplification in urinary bladder cancer. <i>International Journal of Cancer</i> , 2005 , 117, 952-6	7.5	29
51	Expression and amplification of therapeutic target genes in retinoblastoma. <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> , 2005 , 243, 156-62	3.8	11
50	Tissue Microarrays for Miniaturized High-Throughput Molecular Profiling of Tumors 2005 , 345-360		
49	Gene expression profiling of progressive papillary noninvasive carcinomas of the urinary bladder. <i>Clinical Cancer Research</i> , 2005 , 11, 4415-29	12.9	83
48	Tissue microarrays. <i>Methods in Molecular Medicine</i> , 2005 , 114, 257-68		43
47	Tissue microarrays. <i>BioTechniques</i> , 2004 , 36, 98-105	2.5	89
46	Tissue microarrays. <i>Methods in Molecular Medicine</i> , 2004 , 97, 377-89		16
45	Prognostic relevance of gene amplifications and coamplifications in breast cancer. <i>Cancer Research</i> , 2004 , 64, 8534-40	10.1	277
44	KIT (CD117)-positive breast cancers are infrequent and lack KIT gene mutations. <i>Clinical Cancer Research</i> , 2004 , 10, 178-83	12.9	83
43	Loss of SFRP1 is associated with breast cancer progression and poor prognosis in early stage tumors 2004 , 25, 641		13

42	Impaired expression of the cell cycle regulator BTG2 is common in clear cell renal cell carcinoma. <i>Cancer Research</i> , 2004 , 64, 1632-8	10.1	78
41	Prevalence of KIT expression in human tumors. <i>Journal of Clinical Oncology</i> , 2004 , 22, 4514-22	2.2	196
40	E2F3 amplification and overexpression is associated with invasive tumor growth and rapid tumor cell proliferation in urinary bladder cancer. <i>Oncogene</i> , 2004 , 23, 5616-23	9.2	124
39	Deletions of chromosome 8p and loss of sFRP1 expression are progression markers of papillary bladder cancer. <i>Laboratory Investigation</i> , 2004 , 84, 465-78	5.9	125
38	Influence of slide aging on results of translational research studies using immunohistochemistry. <i>Modern Pathology</i> , 2004 , 17, 1414-20	9.8	84
37	High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2004 , 86, 207-13	4.4	195
36	Tissue microarrays for early target evaluation. <i>Drug Discovery Today: Technologies</i> , 2004 , 1, 41-8	7.1	4
35	Tissue microarrays for high-throughput molecular pathology. <i>Annals of Saudi Medicine</i> , 2004 , 24, 169-74	1.6	18
34	Prognostic Molecular Features in Diffuse Large B-Cell Lymphoma from Saudi Arabia.. <i>Blood</i> , 2004 , 104, 4609-4609	2.2	
33	Epstein-Barr Virus Infection Is Not the Sole Cause of High Prevalence for Hodgkin's Lymphoma in Saudi Arabia.. <i>Blood</i> , 2004 , 104, 3120-3120	2.2	
32	Tissue Microarrays in Pathology 2004 , 1271-1276		
31	HER2 analysis in breast cancer: reduced immunoreactivity in FISH non-informative cancer biopsies. <i>International Journal of Oncology</i> , 2004 , 25, 1551-7	1	18
30	Tissue microarray (TMA) applications: implications for molecular medicine. <i>Expert Reviews in Molecular Medicine</i> , 2003 , 5, 1-12	6.7	29
29	Sequence analysis and high-throughput immunohistochemical profiling of KIT (CD 117) expression in uveal melanoma using tissue microarrays. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2003 , 443, 741-4	5.1	48
28	HER-2 and TOP2A coamplification in urinary bladder cancer. <i>International Journal of Cancer</i> , 2003 , 107, 764-72	7.5	84
27	High-throughput tissue microarray analysis of 11q13 gene amplification (CCND1, FGF3, FGF4, EMS1) in urinary bladder cancer. <i>Journal of Pathology</i> , 2003 , 201, 603-8	9.4	78
26	Tissue microarrays in drug discovery. <i>Nature Reviews Drug Discovery</i> , 2003 , 2, 962-72	64.1	150
25	Tissue microarrays in cancer diagnosis. <i>Expert Review of Molecular Diagnostics</i> , 2003 , 3, 421-30	3.8	59

24	Tissue microarrays for miniaturized high-throughput molecular profiling of tumors. <i>Experimental Hematology</i> , 2002 , 30, 1365-72	3.1	86
23	Prognostic relevance of MAGE-A4 tumor antigen expression in transitional cell carcinoma of the urinary bladder: a tissue microarray study. <i>International Journal of Cancer</i> , 2002 , 100, 702-5	7.5	61
22	Analysis of the progression of fibroepithelial tumours of the breast by PCR-based clonality assay. <i>Journal of Pathology</i> , 2002 , 197, 575-81	9.4	76
21	Patterns of chromosomal aberrations in urinary bladder tumours and adjacent urothelium. <i>Journal of Pathology</i> , 2002 , 198, 115-20	9.4	31
20	Amplification pattern of 12q13-q15 genes (MDM2, CDK4, GLI) in urinary bladder cancer. <i>Oncogene</i> , 2002 , 21, 2476-83	9.2	126
19	Predictive molecular pathology. <i>New England Journal of Medicine</i> , 2002 , 347, 1995-6	59.2	25
18	Ductal invasive G2 and G3 carcinomas of the breast are the end stages of at least two different lines of genetic evolution. <i>Journal of Pathology</i> , 2001 , 194, 165-70	9.4	137
17	Comparative genomic hybridization in pineal parenchymal tumors. <i>Genes Chromosomes and Cancer</i> , 2001 , 30, 99-104	5	59
16	Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer. <i>Journal of the National Cancer Institute</i> , 2001 , 93, 1141-6	9.7	248
15	Cytogenetic analysis of multifocal bladder cancer supports a monoclonal origin and intraepithelial spread of tumor cells. <i>Cancer Research</i> , 2001 , 61, 355-62	10.1	78
14	High-throughput tissue microarray analysis of 3p25 (RAF1) and 8p12 (FGFR1) copy number alterations in urinary bladder cancer. <i>Cancer Research</i> , 2001 , 61, 4514-9	10.1	109
13	Comparative methodological analysis of erbB-2/HER-2 gene dosage, chromosomal copy number and protein overexpression in breast carcinoma tissues for diagnostic use. <i>Histopathology</i> , 2000 , 37, 411-9 ³	7.3	49
12	Molecular classification of cutaneous malignant melanoma by gene expression profiling. <i>Nature</i> , 2000 , 406, 536-40	50.4	1647
11	Patterns of chromosomal imbalances in muscle invasive bladder cancer. <i>International Journal of Oncology</i> , 2000 , 17, 1025-9	1	16
10	Comparative genomic hybridization of ductal carcinoma in situ of the breast-evidence of multiple genetic pathways. <i>Journal of Pathology</i> , 1999 , 187, 396-402	9.4	257
9	Different genetic pathways in the evolution of invasive breast cancer are associated with distinct morphological subtypes. <i>Journal of Pathology</i> , 1999 , 189, 521-6	9.4	190
8	Chromosomal Aberrations Associated With Invasion in Papillary Superficial Bladder Cancer. <i>Journal of Urology</i> , 1999 , 162, 621-621	2.5	
7	Comparative genomic hybridization of ductal carcinoma in situ of the breast-evidence of multiple genetic pathways 1999 , 187, 396		1

6	Different genetic pathways in the evolution of invasive breast cancer are associated with distinct morphological subtypes 1999 , 189, 521		2
5	Chromosomal aberrations associated with invasion in papillary superficial bladder cancer. <i>Journal of Pathology</i> , 1998 , 185, 345-51	9.4	114
4	Chromosomal aberrations associated with invasion in papillary superficial bladder cancer 1998 , 185, 345		1
3	Chromosomal aberrations associated with invasion in papillary superficial bladder cancer 1998 , 185, 345		3
2	Comparative genomic hybridization (CGH) analysis of neuroblastomas--an important methodological approach in paediatric tumour pathology. <i>Journal of Pathology</i> , 1997 , 181, 394-400	9.4	83
1	Random forest-based modelling to detect biomarkers for prostate cancer progression		1